Temisis Therapeutics announced that it has received 1.6 million in a round of funding on December 18, 2020. The transaction included participation from returning investor Plant Advanced Technologies SA (ENXTPA:ALPAT) and new investor Financiere Hoche Bains-Les-Bains SA (ENXTPA:MLHBB). As part of the transaction, Financiere Hoche Bains-Les-Bains SA (ENXTPA:MLHBB) acquired 1.54% stake in the company and Plant Advanced Technologies SA (ENXTPA:ALPAT) now holds 98.46% in the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.4 EUR | +2.70% | +8.57% | +34.91% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+34.91% | 13.35M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- ALPAT Stock
- News Plant Advanced Technologies
- Temisis Therapeutics announced that it has received €1.6 million in funding from Financiere Hoche Bains-Les-Bains SA, Plant Advanced Technologies SA